- Home
- MTEM vs EVAX Comparison
MTEM vs EVAX Comparison
Compare MTEM & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTEM
- EVAX
- Stock Information
- Founded
- MTEM 2001
- EVAX 2008
- Country
- MTEM United States
- EVAX Denmark
- Employees
- MTEM N/A
- EVAX N/A
- Industry
- MTEM Biotechnology: Biological Products (No Diagnostic Substances)
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MTEM Health Care
- EVAX Health Care
- Exchange
- MTEM Nasdaq
- EVAX Nasdaq
- Market Cap
- MTEM 9.7M
- EVAX 8.7M
- IPO Year
- MTEM N/A
- EVAX 2021
- Fundamental
- Price
- MTEM $0.35
- EVAX $0.88
- Analyst Decision
- MTEM
- EVAX Strong Buy
- Analyst Count
- MTEM 0
- EVAX 2
- Target Price
- MTEM N/A
- EVAX $11.00
- AVG Volume (30 Days)
- MTEM 15.2M
- EVAX 77.4K
- Earning Date
- MTEM 12-27-2024
- EVAX 10-31-2024
- Dividend Yield
- MTEM N/A
- EVAX N/A
- EPS Growth
- MTEM N/A
- EVAX N/A
- EPS
- MTEM N/A
- EVAX N/A
- Revenue
- MTEM $25,470,000.00
- EVAX $3,295,000.00
- Revenue This Year
- MTEM N/A
- EVAX $4,845.21
- Revenue Next Year
- MTEM N/A
- EVAX $30.30
- P/E Ratio
- MTEM N/A
- EVAX N/A
- Revenue Growth
- MTEM N/A
- EVAX N/A
- 52 Week Low
- MTEM $0.30
- EVAX $0.87
- 52 Week High
- MTEM $4.12
- EVAX $13.61
- Technical
- Relative Strength Index (RSI)
- MTEM 41.77
- EVAX 19.35
- Support Level
- MTEM $0.34
- EVAX $1.08
- Resistance Level
- MTEM $0.78
- EVAX $1.20
- Average True Range (ATR)
- MTEM 0.07
- EVAX 0.18
- MACD
- MTEM 0.01
- EVAX -0.01
- Stochastic Oscillator
- MTEM 5.00
- EVAX 1.11
About MTEM Molecular Templates Inc.
Molecular Templates Inc is a clinical-stage biopharmaceutical company focused on developing therapeutic agents that selectively target tumor cells for the treatment of individuals living with cancer. Its pipeline products are MT-6402, MT-8421 and MT-0169.
About EVAX Evaxion Biotech A/S
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.